Recent Submissions

  • Age, anticoagulants, hypertension and cardiovascular genetic traits predict cranial ischaemic complications in patients with giant cell arteritis

    Chaddock, Natalie J M; Harden, Charlotte J; Sorensen, Louise; Mathieson, Hannah R; Zulcinski, Michal; Lawson, Catherine A; O'Sullivan, Eoin; Mollan, Susan P; Martin, Javier; Mackie, Sarah L; et al. (BMJ Publishing Group, 2024-10-03)
    Objectives: This project aimed to determine whether cranial ischaemic complications at the presentation of giant cell arteritis (GCA) were associated with pre-existing cardiovascular (CV) risk factors, CV disease or genetic risk of CV-related traits. Methods: 1946 GCA patients with clinicodemographic data at GCA presentation were included. Associations between pre-existing CV-related traits (including Polygenic Risk Scores (PRS) for CV traits) and cranial ischaemic complications were tested. A model for cranial ischaemic complications was optimised using an elastic net approach. Positional gene mapping of associated PRS was performed to improve biological understanding. Results: In a sample of 1946 GCA patients (median age=71, 68.7% female), 17% had cranial ischaemic complications at presentation. In univariable analyses, 10 variables were associated with complications (likelihood-ratio test p≤0.05). In multivariable analysis, the two variables with the strongest effects, with or without PRS in the model, were anticoagulant therapy (adjusted OR (95% CI)=0.21 (0.05 to 0.62), p=4.95×10-3) and age (adjusted OR (95% CI)=1.60 (0.73 to 3.66), p=2.52×10-3, for ≥80 years versus <60 years). In sensitivity analyses omitting anticoagulant therapy from multivariable analysis, age and hypertension were associated with cranial ischaemic complications at presentation (hypertension: adjusted OR (95% CI)=1.35 (1.03 to 1.75), p=0.03). Positional gene mapping of an associated transient ischaemic attack PRS identified TEK, CD96 and MROH9 loci. Conclusion: Age and hypertension were risk factors for cranial ischaemic complications at GCA presentation, but in this dataset, anticoagulation appeared protective. Positional gene mapping suggested a role for immune and coagulation-related pathways in the pathogenesis of complications. Further studies are needed before implementation in clinical practice.
  • Transformative deep vein thrombosis prophylaxis with sequential compression devices in the care of hospitalized patients

    Shahbaz, Aaisha; Wannakuwatte, Randev A; Mohammed, Cara; Alzarooni, Abdulaziz; Pendem, Harini; Majeed, Farhat; Kuruba, Venkataramana; Metry, Sherien; Mahajan, Tanvi; Reza, Hasim; et al. (Cureus, 2024-10-01)
    Deep vein thrombosis (DVT) is a critical complication and concern in hospitalized patients due to its significant morbidity and mortality. Given the complex and multifaceted pathophysiology surrounding DVT formation, patients who have had surgical interventions faced acute or chronic trauma and prolonged immobility are at substantially high risk. Identifying these risk factors early is essential for early intervention and prophylaxis. Current standard-of-care prophylaxis for DVT includes pharmacological agents such as anticoagulants, and recently, there has been an increase in the use of mechanical medical devices such as sequential compression devices (SCDs). Pharmacological prophylaxis, while shown to be effective in some patients, carries certain risks of complications such as bleeding. SCDs offer a safer and more effective approach for these patients. SCDs function by artificially replicating the "pumping mechanism" present in the soleus muscle to enhance venous return and reduce stasis. Various types of SCDs, namely intermittent pneumatic compression and graduated compression stockings, have demonstrated clinical efficacy when used as an adjunctive intervention with anticoagulant medications. This narrative review explores the pathophysiology, risk factors, and prophylactic measures for DVT, focusing on the use of SCDs as a non-pharmacological intervention. Through synthesizing evidence from various studies obtained from PubMed, MEDLINE, and Cochrane Library and evaluating the benefits and limitations of SCD use, this review highlights the need for tailored prophylactic strategies, considering patient-specific risk factors and preferences.
  • Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies.

    Warnatz, Klaus; Jolles, Stephen; Agostini, Carlo; Vianello, Fabrizio; Borte, Michael; Bethune, Claire; Grigoriadou, Sofia; Richter, Alex; Jain, Rashmi; Lowe, David M; et al. (Academic Press, 2022-02-01)
    Many patients with immunodeficiencies require lifelong immunoglobulin replacement therapy (IgRT). In a multicenter, randomized, open-label, crossover, non-inferiority 3-month-trial, we compared the impact of the subcutaneous immunoglobulin Gammanorm® administered via pump or syringe (rapid push). Primary endpoint was the life quality index (LQI), secondary endpoints were QoL (SF36v2), satisfaction (TSQM-11), disease and treatment burden (PRISM), incidence of infections and adverse events (AE), treatment costs, and IgG levels. 28/30 patients completed the study. Most of the endpoints were comparable. Drug administrations with rapid push were more frequent, but reduced total time expenditure and some costs. Of the TSQM-11/LQI/SF36 components only "treatment interference with daily activities" was superior with pump and two QoL domains with rapid push. Both delivery devices showed favorable safety. Rapid push was preferred by 34.5% of patients. It proved to be an efficacious and cost-effective alternative to pumps adding to patient choice and increasing flexibility during long-term IgRT.
  • The management of Castleman disease.

    Lomas, Oliver C; Streetly, Matthew; Pratt, Guy; Cavet, Jim; Royston, Daniel; Schey, Stephen; Ramasamy, Karthik; Pratt, Guy; Haematology; Medical and Dental (Wiley-Blackwell, 2021-08-02)
    No abstract available
  • Prehospital blood transfusion for haemorrhagic shock - Authors' reply

    Crombie, Nick; Bishop, Jon; Ives, Natalie; Perkins, Gavin D; University Hospitals Birmingham NHS Foundation Trust; University of Birmingham; University of Warwick (Elsevier, 2022-06-09)
    No abstract available
  • SARS-CoV-2-specific T cell responses are not associated with protection against reinfection in hemodialysis patients.

    Shankar, Sushma; Beckett, Joseph; Tipton, Tom; Ogbe, Ane; Kasanyinga, Mwila; Dold, Christina; Lumley, Sheila; Dengu, Fungai; Rompianesi, Gianluca; Elgilani, Faysal; et al. (Wolters Kluwer Health, 2022-03-31)
    Patients on hemodialysis (HD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mount poor neutralizing antibody responses after two-dose vaccination. Although serological responses have been associated with reduced rates of reinfection, the relationship between cellular immunogenicity and protection has not been established. We report, for the first time, high incidence of reinfection in patients on HD who are vaccine naive (25%), which identifies that T cell responses do not predict protection against reinfection. Instead, patients on HD who went on to become reinfected had mounted highly variable and sometimes robust proliferative T cell responses to a broad array of SARS-CoV-2 peptide pools during the primary infection. The understanding that SARS-CoV-2–specific T cell responses are not predictive of protection against future infection will be a critical issue when measuring clinical efficacy of vaccination in these vulnerable cohorts, particularly when facing rapidly emerging variants of concern.
  • The three musketeers: uniting against CLL.

    Kwok, Marwan; Stankovic, Tatjana (Elsevier, 2022-03-03)
    No abstract available
  • Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS.

    Miesbach, Wolfgang; Curry, Nicola; Knöbl, Paul; Percy, Charles; Santoro, Rita; Schmaier, Alvin H; Trautmann-Grill, Karolin; Badejo, Kayode; Chen, Jie; Nouri, Masoud; et al. (SAGE Publications, 2024-09-02)
    Background: Recombinant porcine factor VIII (rpFVIII; susoctocog alfa) is indicated for the treatment of bleeding events (BEs) in adults with acquired hemophilia A (AHA). Objectives: To assess the safety, utilization, and effectiveness of rpFVIII in clinical practice. Design: EU post-authorization safety study (PASS) (NCT03199794) was a multicenter, noninterventional, post-authorization safety study conducted in adults with AHA. Methods: Data were collected retrospectively or prospectively for up to 180 days after the last rpFVIII dose. The primary objective was safety, as assessed by adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) (e.g. immunogenicity, hypersensitivity reactions, thromboembolic events). Secondary endpoints included immunogenicity, rpFVIII hemostatic effectiveness, and rpFVIII utilization. Results: Fifty patients were enrolled; 31 completed the study. The median (range) follow-up for patients who completed or discontinued the study was 178 (26-371) days. The median (range) first dose of rpFVIII was 54.0 (11-200) U/kg. Thirty patients reported 46 SAEs; 5 SAEs were considered probably related to rpFVIII, of which 1 was lack of rpFVIII efficacy, and 4 were AESIs: drug resistance due to FVIII inhibition (one patient), antibody test positive for anti-pFVIII inhibitors (one patient), and de novo anti-pFVIII inhibitors (two patients). No hypersensitivity reactions or thromboembolic events were reported. Of the 50 initial BEs, 37 resolved [in a median (interquartile range) of 8.0 (4.0-16.0) days]. Conclusion: Results from this real-world study support the use of rpFVIII for AHA, aligning with findings from the clinical trial of rpFVIII (NCT01178294) in the treatment of BEs in adults with AHA. Trial registration: EUPAS16055; NCT03199794.
  • Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.

    Walter, Roland B; Potter, Victoria; Craddock, Charles; Craddock, Charles; Haematology; Medical and Dental (Elsevier, 2024-09-06)
    The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted increasing use of allogeneic hematopoietic cell transplantation (allo-HCT) in adults age ≥70 with AML. However, while potentially curative, non-relapse mortality and relapse represent the main causes of treatment failure, highlighting the importance of refining both patient selection and transplant strategies. At the same time, continuously evolving non-transplant therapies and transplant technologies mandate prospective trials (re-)examining the role of allo-HCT and its optimal delivery.
  • Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms.

    Faustini, Sian; Chan, Y L Tracey; Evans, Lilli; Collman, Emily; Rapson, Alec; Backhouse, Claire; Emery, Annabelle; Campbell, John P; Moore, Sally; Richter, Alex; et al. (Nature Publishing Group, 2024-09-07)
    No abstract available
  • Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: a British Society of Haematology and UK Myeloma Society Good Practice Paper

    Kaiser, Martin; Goh, Vicky; Stern, Simon; Spencer, Nicholas; Rabin, Neil; Ramasamy, Karthik; Lawless, Sarah; Soutar, Richard; Ashcroft, John; Pratt, Guy; et al. (Wiley-Blackwell, 2024-09-09)
    This Good Practice Paper provides recommendations for the use of advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma. It describes how advanced imaging contributes to optimal healthcare resource utilisation by in newly diagnosed and relapsed myeloma, and provides a perspective on future directions of myeloma imaging, including machine learning assisted reporting.
  • Transfusion camp: the UK experience and its value in improving knowledge of transfusion medicine among postgraduate trainees.

    Aggarwal, Asha; Kaushik, Kunaal; Morton, Suzy; Danaee, Anicee; Gurung, Kamala; Robinson, Susan; Kapitany, Casey; Charge, Sophie; Lin, Yulia; Desborough, Mike; et al. (Blackwell Scientific Publications, 2024-08-08)
    Objectives: To report the UK experience of rolling out Transfusion Camp. Background: Transfusion Camp is a structured education programme developed in Toronto, with the aim of reducing knowledge gaps in transfusion medicine in postgraduate trainees. It consists of didactic lectures viewed online by the participants, then interactive, locally delivered seminars. Since 2015, it has been rolled out in the United Kingdom, and is now available in four centres. Here, we report the UK experience of Transfusion Camp and outcomes. Methods: Trainees are recruited via the training programme directors in each region. Pre- and post-course assessments are administered using the validated BEST (Biomedical Excellence for Safer Transfusion) test, with possible scores 0-20, and confidence measured on an A-E Likert scale. Results: Since 2015, 130 trainees have participated in Transfusion Camp in the United Kingdom. Trainees from all specialties significantly improved their BEST-test scores after attending the course (mean score 11.6/20 before the course, compared with 14.3/20 after the course), and confidence in managing transfusion-related issues was also significantly improved. Conclusion: We recommend that all centres consider offering Transfusion Camp to trainees in haematology and other specialties that frequently use blood transfusions, such as anaesthesia/ICU, Internal Medicine and others.
  • Use of IV immunoglobulin to treat steroid resistant, immune checkpoint inhibitor-induced pure red cell aplasia: A case report

    Sherratt-Mayhew, Sam; Nicolson, Phillip L R; Nicolson, Phillip L R; Haematology; Medical and Dental; University of Birmingham; University Hospitals Birmingham NHS Foundation Trust (John Wiley & Sons, 2024-06-16)
    Pure red cell aplasia (PRCA) is characterised by normocytic normochromic anaemia, reticulocytopenia and reduced erythroid precursors in bone marrow. PRCA as an immune-related adverse event secondary to immune checkpoint inhibitor (ICI) therapy is rare. Steroids are usually used first line to treat ICI-induced PRCA. Here, we report a case of ICI-induced PRCA with no response to steroids but where intravenous (IV) immunoglobulin was successfully used second line. ICI therapy was reinitiated following PRCA resolution. PRCA recurrence did not occur.
  • Extramedullary chronic phase chronic myeloid leukaemia (CML) involving the central nervous system: A case report

    Deshpande, Akshay; Osman, Dina; Murthy, Vidhya; Hussein, Hayder; Deshpande, Akshay; Osman, Dina; Murthy, Vidhya; Hussein, Hayder; Oncology; Haematology; et al. (John Wiley & Sons, 2024-06-25)
    Chronic myeloid leukaemia (CML) has been classically described as a disease restricted to the bone marrow with very few reports of extramedullary involvement. CNS involvement with CML has been described in the literature as an aggressive disease in the leukaemic phase either preceding or coexisting with medullary blast crisis or seen in patients with long-term Imatinib therapy. No treatment consensus exists for this patient group and outcomes remain poor. We hereby present a very rare report of CNS involvement with chronic phase CML at diagnosis in a patient who presented with raised intracranial pressure and cranial nerve palsies.
  • PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia

    Kothari, Jaimal; Eyre, Toby; Rismani, Ali; Ediriwickrema, Kushani; Edwards, Darren; Galani, Sevasti; Wilson, William; Lawrie, Anthony; Clifton-Hadley, Laura; McCarthy, Helen; et al. (Wiley-Blackwell, 2024-08-19)
    The optimal therapeutic approach for relapsed/refractory (R/R) Waldenström's Macroglobulinaemia (WM) has not been clearly defined, especially after treatment with chemoimmunotherapy (CIT) and covalent Bruton's tyrosine kinase inhibitors (cBTKi). The PembroWM trial is a multi-centre, phase II, single-arm study assessing the safety, tolerability and efficacy of rituximab with pembrolizumab in R/R WM patients who had received at least one prior line of treatment, with all having relapsed post-CIT and most also exposed to cBTKi. A total of 17 patients were enrolled, with a median age of 70, and median of three prior lines of therapy with 15 either refractory or intolerant of a cBTKi. A significant proportion was identified as genomically high risk with BTKC481, CXCR4 and MYD88 L265P wild-type aberrations. Twenty-four-week overall response rate was 50% (60% CI 39.3%-60.7%), and median duration of response was 11.6 months (IQR: 6.3-17). The median progression-free survival was 13.6 months (95% CI 3-19.8), and the median overall survival (OS) was not reached. Treatment was well tolerated, with minimal numbers of immune-mediated AEs typically seen with checkpoint inhibitors. PembroWM is the first study to evaluate the feasibility of PD-1 axis modulation in WM and has shown that in combination with Rituximab the combination is safe and deliverable.
  • Nodular lymphocyte predominant hodgkin lymphoma with aberrant immunophenotype or variant histopathology: insights from case series of three patients.

    Chander, Gurvin; Dassanayake, Hansini; Kaparou, Maria; Ahmed, Maria; Kishore, Bhuvan; Nikolousis, Emmanouil; Kanellopoulos, Alexandros; Ahmed, Maria; Kishore, Bhuvan; Doctors; et al. (International Institute of Anticancer Research, 2021-08)
    Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) with variant histopathology or aberrant immunophenotype is exceedingly rare and there is paucity of data with regards to its clinical characteristics and course. Case report: Herein, we present three cases of NLPHL with aberrant immunophenotype or variant histopathological picture, which displayed distinct clinical and imaging findings. These case reports involved a patient with CD30 and CD20 positivity without Reed-Sternberg cells present, a NLPHL patient with aggressive, persistent disease activity with progressive transformation to germinal centres, and a patient with combined morphology of NLPHL and classical Hodgkin's lymphoma. Conclusion: Aberrant immunophenotype/variant NLPHL might represent a distinct form of NLPHL, sharing characteristics with classical Hodgkin, non-Hodgkin lymphomas or benign, progressive transformation of germinal centre lymphadenopathy.
  • Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis.

    Craven, Brian; Lester, William; Boyce, Sara; Thomas, Will; Kanny, Angela; Davies, Claire; Pavord, Sue; Hermans, Joannes; Makris, Michael; Bart-Smith, Emily; et al. (Elsevier, 2022-04-21)
    The COVID-19 pandemic has resulted in the rapid development of a range of vaccines against SARS-CoV-2. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare but life-threatening complication of primarily adenoviral-based vaccines associated with the presence of antibodies to a PF4/polyanion neoepitope and measured by using enzyme-linked immunosorbent assays. Presented are serial anti-PF4/polyanion antibody, platelet, and D-dimer measurements in a large cohort of patients and their relation to relapse. Overall, 51% of patients using the Stago assay had persistently positive anti-PF4/polyanion levels 100 days' postdiagnosis, whereas 94% of patients monitored by using the Immucor assay remain positive. The median duration of positivity of the PF4 assay is 87 days, with 72% of patients remaining positive after a median follow-up of 105 days. The use of plasma exchange seemed to reduce anti-PF4/polyanion levels and increase platelet counts in the acute setting more rapidly than other therapies. The rate of relapse in this study was 12.6%, with all relapsed cases exhibiting persistently positive PF4 antibodies and falling platelet counts. Only one patient had extension of their thrombosis. Overall, despite the persistence of PF4 antibodies in 72% of patients, the rate of relapse was low and did not seem to result in recrudescence of the aggressive clinical picture seen at index presentation. Monitoring of these patients in the UK cohort is ongoing and will aid in definition of the natural history of this novel condition.
  • Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.

    Döhner, Hartmut; DiNardo, Courtney D; Wei, Andrew H; Löwenberg, Bob; Appelbaum, Frederick; Craddock, Charles; Dombret, Hervé; Ebert, Benjamin L; Fenaux, Pierre; Godley, Lucy A; et al. (Elsevier, 2024-08-12)
    The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
  • New pharmacological tools to target leukocyte trafficking in lung disease.

    Belchamber, Kylie B R; Hughes, Michael J; Spittle, Daniella A; Walker, Eloise M; Sapey, Elizabeth; Sapey, Elizabeth; Medicine; Medical and Dental (Frontiers Research Foundation, 2021-07-21)
    Infection and inflammation of the lung results in the recruitment of non-resident immune cells, including neutrophils, eosinophils and monocytes. This swift response should ensure clearance of the threat and resolution of stimuli which drive inflammation. However, once the threat is subdued this influx of immune cells should be followed by clearance of recruited cells through apoptosis and subsequent efferocytosis, expectoration or retrograde migration back into the circulation. This cycle of cell recruitment, containment of threat and then clearance of immune cells and repair is held in exquisite balance to limit host damage. Advanced age is often associated with detrimental changes to the balance described above. Cellular functions are altered including a reduced ability to traffic accurately towards inflammation, a reduced ability to clear pathogens and sustained inflammation. These changes, seen with age, are heightened in lung disease, and most chronic and acute lung diseases are associated with an exaggerated influx of immune cells, such as neutrophils, to the airways as well as considerable inflammation. Indeed, across many lung diseases, pathogenesis and progression has been associated with the sustained presence of trafficking cells, with examples including chronic diseases such as Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis and acute infections such as Pneumonia and Pneumonitis. In these instances, there is evidence that dysfunctional and sustained recruitment of cells to the airways not only increases host damage but impairs the hosts ability to effectively respond to microbial invasion. Targeting leukocyte migration in these instances, to normalise cellular responses, has therapeutic promise. In this review we discuss the current evidence to support the trafficking cell as an immunotherapeutic target in lung disease, and which potential mechanisms or pathways have shown promise in early drug trials, with a focus on the neutrophil, as the quintessential trafficking immune cell.
  • Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.

    Pasi, K John; Laffan, Michael; Rangarajan, Savita; Robinson, Tara M; Mitchell, Nina; Lester, Will; Symington, Emily; Madan, Bella; Yang, Xinqun; Kim, Benjamin; et al. (Wiley, 2021-08-11)
    Introduction: Valoctocogene roxaparvovec is an investigational AAV5-based factor VIII (FVIII) gene therapy that has demonstrated sustained clinical benefit in people with severe haemophilia A. Aim: To report safety, tolerability, efficacy, and quality of life (QOL) among participants who received valoctocogene roxaparvovec in a phase 1/2 clinical study (NCT02576795). Methods: Men ≥18 years of age with severe haemophilia A (FVIII ≤1 IU/dl) without history of FVIII inhibitors or anti-AAV5 antibodies received a single infusion of valoctocogene roxaparvovec and were followed for 5 years (6 × 1013 vg/kg dose, n = 7) and 4 years (4 × 1013 vg/kg dose, n = 6). Results: Over the past 2 years, few adverse events and no FVIII inhibitors were reported. Per chromogenic substrate (CSA) assay at years 5 and 4, four of seven and three of six participants in the 6 × 1013 and 4 × 1013 vg/kg cohorts, respectively, maintained median FVIII levels >5 IU/dl, corresponding to mild haemophilia. By regression analysis, rate of change in FVIII activity was -0.14 (95% confidence interval [CI]: -.32 to .03) IU/dl/wk in the 6 × 1013 vg/kg cohort in year 5 and -.06 (95% CI: -.14 to .01) IU/dl/wk in the 4 × 1013 vg/kg cohort in year 4. No participants resumed FVIII prophylaxis, and eight of 13 participants reported zero bleeds in the past 2 years. Improved QOL from baseline persisted in the 6 × 1013 vg/kg cohort; all six Haemo-QOL-A domain scores increased. For the 4 × 1013 vg/kg cohort, high baseline Haemo-QOL-A scores persisted. Conclusion: These results demonstrate transgene expression and haemostatic response for up to 5 years in individuals with haemophilia A.

View more